From the Research
Nintedanib is not specifically contraindicated in patients with abdominal aortic aneurysm (AAA), but caution and close monitoring are advised due to its potential effects on vascular tissues. The official contraindications for nintedanib include hypersensitivity to the drug or its components, pregnancy, and severe liver impairment 1. However, patients with AAA should be monitored carefully while on nintedanib due to its potential effects on vascular tissues. Nintedanib is a tyrosine kinase inhibitor that inhibits vascular endothelial growth factor receptors (VEGFR), which could theoretically impact vascular integrity.
While taking nintedanib, patients with AAA should have regular monitoring of their aneurysm size and symptoms. The standard dosing of nintedanib is typically 150 mg twice daily with food, though dose reductions to 100 mg twice daily may be necessary if side effects occur 2. Common side effects include diarrhea, nausea, and elevated liver enzymes. Patients with AAA should promptly report any new or worsening abdominal or back pain while on nintedanib therapy, as these could potentially indicate aneurysm expansion or complications.
Some key points to consider when prescribing nintedanib to patients with AAA include:
- Close monitoring of aneurysm size and symptoms
- Regular assessment of liver function and adjustment of dose as needed
- Prompt reporting of any new or worsening abdominal or back pain
- Consideration of alternative treatments if nintedanib is not tolerated or if aneurysm expansion occurs. It's worth noting that the most recent and highest quality study on this topic is from 2019 1, which provides information on the clinical pharmacokinetics and pharmacodynamics of nintedanib, but does not specifically address its use in patients with AAA. However, based on the available evidence, it is recommended to exercise caution and closely monitor patients with AAA who are taking nintedanib.